A case of an intramesenteric GIST accurately diagnosed and completely resected by PET-CT and laparoscopy after gastrectomy for gastric cancer

Case Report

A 62-year-old man underwent distal gastrectomy for gastric cancer. The pathological diagnosis was pT3N0M0 Stage II A according to the TNM Classification of Malignant Tumors, 8th Edition. In our hospital, follow-up chest and abdominal CT are performed every 6 months for 5 years after gastrectomy. About 2 years later, follow-up CT scan revealed a mesenteric tumor. CT also showed the absence of the other evidence of recurrence of the gastric cancer, such as ascites, distant metastatic tumor and remnant gastric tumor (Fig. 1). The mesenteric tumor had not been identifiable on previous images after gastrectomy; thus, this image was the first image on which GIST was identified. Positron emission tomography (PET)-CT was performed to evaluate the mesenteric tumor and identify other tumors, showing that the maximum standardized uptake value (SUV max) of the mesenteric tumor was 2.9, with no other tumors present in the entire body (Fig. 2). The mesenteric tumor was deemed to be a resectable tumor such as a GIST, desmoid tumor or malignant lymphoma, and not peritoneal dissemination because CT and PET-CT revealed no other tumors.

Laparoscopic surgery was performed to diagnose and then resect the mesenteric tumor. The laparoscopic
Figure 1. CT finding. Follow-up CT after gastrectomy for gastric cancer revealed a mesenteric tumor. There were no other malignant findings.

Figure 2. PET-CT finding. PET-CT showed that the maximum standardized uptake value (SUV max) of the mesenteric tumor was 2.9, with no other tumors present in the whole body.

Figure 3. Laparoscopy finding. Laparoscopy showed a tumor in the mesentery of the small bowel, not arising from the bowel wall, with no obvious metastatic tumors of the liver or peritoneum.

findings revealed that the tumor existed in the mesentery of the small bowel, and not arisen from the bowel wall, with no obvious metastatic tumors of the liver or peritoneum (Fig. 3). Subsequently, partial resection of the small bowel and mesentery with an adequate margin was performed.

The macroscopic evaluation of the surgical specimen revealed an intramesenteric tumor (45 × 35 × 20 mm in size) of the small bowel, without exposure to the abdominal cavity or the bowel lumen (Fig. 4). The postoperative course was uneventful. The pathological findings showed that the mesenteric tumor was a GIST that was c-kit-positive and CD34-, SMA- and S100-negative, with a low Ki-67 proliferation index (<5%) (Fig. 5). Because the tumor was considered to have a low risk of recurrence (<5 cm, low Ki-67 index, and not ruptured), adjuvant therapy was not performed. At 10 months after surgery, he remains free from recurrence of the GIST or gastric cancer.

DISCUSSION

Complete surgical resection is the standard treatment for a localized GIST, and the relapse-free survival and overall survival rates are good after the complete resection, especially in low- or intermediate-risk group [3, 4, 6]. It is important to make an accurate differential diagnosis of GIST for the complete resection. However, GISTs are sometimes asymptomatic until the advanced stages because of their submucosal localization and noninvasive behavior, so an accurate diagnosis is often difficult [7]. In the present case, the intramesenteric GIST was asymptomatic and diagnosed by the follow-up CT after the gastrectomy for gastric cancer.

While the mesenteric tumor was detected by the follow-up CT, the differential diagnosis between GIST and a metastatic tumor of gastric cancer was very important, as the treatment strategies for these tumors are very different. The prognosis is very poor for metastatic tumors of gastric cancer, and treatments for recurrent gastric cancer include systemic chemotherapy, cytoreductive surgery with hyperthermic intraperitoneal chemotherapy and palliative treatment [1, 2, 8, 9]. In contrast, the prognosis is good after the complete resection for GISTs [3-6]. The relapse-free survival is good after the complete resection of GISTs with a low or intermediate risk of recurrence [4, 10].

In the present case, PET-CT was particularly helpful for distinguishing GIST from recurrence after gastrectomy for gastric cancer. Discussions about the differences in the SUV max on PET-CT between GISTs and metastatic tumors of gastric cancer are rare. Fluorodeoxyglucose-PET is reportedly useful for diagnosing recurrent gastric
A case of an intramesenteric GIST

Figure 5. Pathological findings (a: hematoxylin and eosin staining, b: immunohistochemical staining for c-kit). Pathological findings showed that the mesenteric tumor was a GIST and c-kit-positive and CD34-, SMA- and S100-negative, with a low Ki-67 proliferation index (<5%).

cancer, and the median SUV max of recurrent disease was ≥4.0 [11, 12]. However, Iwamura et al. reported that the SUV max of GISTs with a low mitotic index was significantly lower (2.4 ± 4.2) than that of GISTs with a high mitotic index (9.6 ± 7.6), indicating that the SUV max reflects the cell proliferation of GISTs [13]. These studies suggest that the SUV max of GIST with a low mitotic index might be lower than that of metastatic tumors of gastric cancer.

In the present case, the SUV max of the mesenteric tumor was 2.9, and there was no other metastatic tumor in the whole body. The low SUV max and presence of a single tumor indicated that tumor was a resectable tumor. After the diagnosis, we performed laparoscopic surgery. Observation with a laparoscope showed a mesenteric tumor at the small bowel, with no metastatic tumor. In advanced gastric cancer, staging laparoscopy is frequently performed to assess the gastric tumor and metastatic lesions, particularly in cases with peritoneal deposits [14]. Staging laparoscopy avoids unnecessary laparotomy and the morbidity of the laparotomy is minimal. In the present case, laparoscopic surgery was useful for estimating the resectability of the tumor and checking for peritoneal dissemination and other metastatic tumors.

CONFLICT OF INTEREST STATEMENT
The authors declare that they have no interest.

FUNDING
The authors received no funding for this study.

AUTHORS’ CONTRIBUTIONS
Manabu Sato drafted the manuscript. K.F. and Masayuki Sato supervised the writing of the manuscript. Manabu Sato, Masayuki Sato, T.Y., A.K. and Y.S. provided managements of the patient. All authors read and approved the final manuscript.

CONSENT FOR PUBLICATION
Written informed consent was obtained from the patient for the publication of the case and all accompanying images.

REFERENCES
1. Manzanedo I, Pereira F, Serrano Á, Pérez-Viejo E. Review of management and treatment of peritoneal metastases from gastric cancer origin. J Gastrointest Oncol 2021;12:S20–9.
2. Kitayama J, Ishigami H, Yamaguchi H, Sakuma Y, Horie H, Hosoya Y, et al. Treatment of patients with peritoneal metastases from gastric cancer. Ann Gastroenterol Surg 2018;2:116–23.
3. Parab TM, DeRogatis MJ, Boaz AM, Grasso SA, Issack PS, Duarte DA, et al. Gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol 2019;10:144–54.
4. Poveda A, García Del Muro X, López-Guerrero JA, Cubedo R, Martínez V, Romero I, et al. GEIS guidelines for gastrointestinal sarcomas (GIST). Cancer Treat Rev 2017;55:107–19.
5. Miettinen M, Lasota J. Gastrointestinal stromal tumors. Gastroenterol Clin N Am 2013;42:399–415.
6. Akahoshi K, Oya M, Koga T, Shiratsuchi Y. Current clinical management of gastrointestinal stromal tumor. World J Gastroenterol 2018;24:2806–17.
7. Nishida T, Blay J-Y, Hirotta S, Kitagawa Y, Kang Y-K. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer 2016;19:3–14.
8. Kwon HR, Park K, Park S, Kwon HW, Kim S. Prognostic value of metabolic information in advanced gastric cancer using preoperative 18F-FDG PET/CT. Nucl Med Mol Imaging 2019;53:386–95.
9. Yoshida K, Yamaguchi K, Okamura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer 2016;19:329–38.
10. Guller U, Tarantino I, Cerny T, Ulrich A, Schmied BM, Warschkow R. Revisiting a dogma: similar survival of patients with small bowel and gastric GIST. A population-based propensity score SEER analysis. Gastric Cancer 2017;20:49–60.
11. Shimada H, Okazumi S, Koyama M, Murakami K. Japanese Gastric Cancer Association Task Force for Research Promotion: clinical utility of 18F-fluorodeoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature. Gastric Cancer 2011;14:13–21.
13. Iwamuro M, Miyahara K, Sakaguchi C, Takenaka R, Kobayashi S, Mouri H, et al. Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography in gastric mesenchymal tumors. J Clin Med 2020;9:1301.
14. Fukagawa T. Role of staging laparoscopy for gastric cancer patients. Ann Gastroenterol Surg 2019;3:496–505.